Immutep presents positive IMP761 preclinical results

8 March 2019 |

Immutep today announced positive results from its preclinical study of IMP761, a novel LAG3 agonist antibody being developed for the treatment of autoimmune diseases. The results were presented at the 14th Congress of European Crohn’s and Colitis Organisation (ECCO) Conference in Denmark.

Consistent with earlier in vitro studies conducted by Immutep on the immunosuppressive activity of IMP761, this new study in a non-human primate animal model showed that IMP761 decreases inflammatory T cell infiltration induced by intra-dermal injection of an antigen.

Read the full press release


News & opinion

Member Directory